The Neuroprotective properties of Alpha-synuclein

α-突触核蛋白的神经保护特性

• 批准号: nhmrc : 457621
• 负责人: Prof James Vickers
• 金额: $ 21.57万
• 依托单位: Menzies Institute for Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/neuroprotective-properties-alpha-synuclein/76659
• 关键词: Neuroprotective; properties; Alpha; synuclein

Parkinson's Disease (PD) is one of the most common neurodegenerative disorders. Its incidence increases steadily with age affecting approximately 1% of the population at age 65 and up to 5% by the age of 85. At the time of diagnosis, patients suffer from a range of motor impairments that worsen over time. Pathologically these patients are characterised by the accumulation of a protein known as alpha-synuclein in specific types of nerve cells in their brain. However, the function of this protein is unknown. This proposal will clarify the role of alpha-synuclein in PD and normal CNS function and provide new potential therapeutic targets for the treatment of PD and other neurodegenerative disorders in which oxidative stress, excitotoxicity and central nervous system trauma have been implicated.

帕金森病（Parkinson's Disease，PD）是最常见的神经退行性疾病之一。其发病率随着年龄的增长而稳步增加，在65岁时影响约1%的人口，到85岁时高达5%。在诊断时，患者患有一系列运动障碍，随着时间的推移而恶化。病理上，这些患者的特征是在大脑中特定类型的神经细胞中积累了一种称为α-突触核蛋白的蛋白质。然而，这种蛋白质的功能尚不清楚。该提案将阐明α-突触核蛋白在PD和正常CNS功能中的作用，并为治疗PD和其他涉及氧化应激、兴奋性毒性和中枢神经系统创伤的神经退行性疾病提供新的潜在治疗靶点。